Deans' stroke musings: Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, September 1, 2025

Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis

You'll have to ask your competent? doctor why the hell edaravone is approved in Japan since 2001 but not the US. If your doctor doesn't know this off the top of the head; you DON'T have a functioning stroke doctor!

Has your stroke hospital done anything with edaravone in the last decade?

edaravone (12 posts to November 2011)

The latest here:

Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis

Haobo Gao^†

Hongtu Tan^†

Jiabin Wang

Dongyi Yang

Yangyang Liu

Tao Wu^*

Department of Intervention, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

Background: In China, edaravone dexborneol (ED) is often used to treat acute ischemic stroke (AIS), but internationally, ED is not commonly used. This study aimed to conduct a meta-analysis on the application of ED in AIS, so as to provide reference and guidance for clinical use in the future.

Methods: Pubmed and Web of Science databases were searched for articles on ED in the treatment of AIS. Two researchers independently searched the articles based on pre-specified inclusion (randomized controlled trial, complete data, correct logic, English literature, etc.) and exclusion criteria (studies lacking objective reference standards, studies with follow-up success rates below 80%, etc.), and duplicate articles were excluded using Endnote. The search was set for the build time to December 2024. Then, the initially enrolled articles were subjected to information and data extraction and crosschecking, followed by meta analysis using the RevMan 5.3 software after screening. Primary outcome measures included clinical efficacy, safety, and NIHSS.

Results: A total of 5 articles were included after screening, totaling 2,651 study participants. Subjects in the 5 articles were divided into an experimental group (ED treatment, n = 1,465) and a control group (other treatment regimen(s), n = 1,226). All the articles were of high quality and high reference value. According to Meta-analysis, no statistically significant difference was observed in the incidence of adverse reactions between the ED and control groups (95%CI = 0.67 ~ 1.04, p = 0.11), but the clinical efficacy in the experimental group exhibited significantly better outcomes compared to the control group (95%CI = 0.03 ~ 0.09, p = 0.0002). In addition, NIHSS (95%CI = −4.67 ~ −0.13, p = 0.04) and hs-CRP (95%CI = −1.90 ~ −0.23, p = 0.01) were lower in the experimental group than in the control group. Funnel plots were drawn for outcome measures with heterogeneity. The results showed that the funnel plot of the NIHSS scores and hs-CRP were basically symmetrical.

Conclusion: While ED demonstrates short-term efficacy in improving neurological outcomes, its clinical applicability remains uncertain due to unresolved questions about drug diffusion and delivery in human brain tissue, which may fundamentally limit its long-term benefits.